Pegaspargase for Treating Acute Lymphoblastic Leukaemia (TA408)

Technology Appraisal Guidance No. 408

Source: National Institute for Health and Care Excellence

1. Guidance

1.1 Pegaspargase, as part of antineoplastic combination therapy, is recommended as an option for treating acute lymphoblastic leukaemia in children, young people and adults only when they have untreated newly diagnosed disease.

1.2 This guidance is not intended to affect the position of patients whose treatment with pegaspargase was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop. For children and young people, this decision should be made jointly by the clinician and the child or young person, or the child or young person's parents or carers.


    The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at

    This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

    © Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

    Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email:

    Pegaspargase for treating acute lymphoblastic leukaemia

    Issue Date: September 2016

    Have you registered with us yet?

    Register now to enjoy more articles and free email bulletins

    Already registered?
    Sign in

    More from MIMS

    Antidiabetic Agents, Use in Renal Impairment

    Antidiabetic Agents, Use in Renal Impairment

    Dosing of diabetes drugs in patients with renal impairment.

    Insulin Delivery Devices

    Insulin Delivery Devices

    Features and compatibility of insulin pens.

    Drug shortages - live tracker

    Drug shortages - live tracker

    Check on the latest drug supply issues with MIMS' shortages...

    Blood Glucose Testing Strips and Meters

    Blood Glucose Testing Strips and Meters

    Compatible test strips for blood glucose meters.